

Appl. No. : 09/786,043  
Filed : February 27, 2001

complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>2 or a derivative homologue or mimetic thereof or having at least about 45% or greater similarity to at least 10 contiguous amino acids in <400>2.

111 103. (NEW) An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1 or a derivative or homologue thereof capable of hybridizing to <400>1 under low stringency conditions.

112 104. (NEW) An isolated nucleic acid molecule according to Claim 103 which further encodes an amino acid sequence substantially as set forth in <400>2 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.

113 105. (NEW) An isolated nucleic acid molecule according to Claim 102 substantially as set forth in <400>1.

114 106. (NEW) An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>4 or a derivative, homologue or mimetic thereof or having at least about 45% or greater similarity to at least 10 contiguous amino acids in <400>4.

115 107. (NEW) An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>3 or a derivative or homologue thereof capable of hybridizing to <400>3 under low stringency conditions.

116 108. (NEW) An isolated nucleic acid molecule according to Claim 107 which further encodes an amino acid sequence substantially as set forth in <400>4 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>4.

117 109. (NEW) An isolated nucleic acid molecule according to Claim 106 substantially as set forth in <400>3.

118 110. (NEW) An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>7 or a derivative, homologue or mimetic thereof or having at least about 45% or greater similarity to at least 10 contiguous amino acids in <400>7.

Appl. No. : 09/786,043  
Filed : February 27, 2001

111 (NEW) An isolated nucleic acid molecule or derivative, homologue or analogue thereof comprising a nucleotide sequence substantially as set forth in one of <400>5 or <400>6 or a derivative or homologue thereof capable of hybridizing to one of <400>5 or <400>6 under low stringency conditions.

112 (NEW) An isolated nucleic acid molecule according to Claim 111 which further encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>7 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>7.

113 (NEW) An isolated nucleic acid molecule according to Claim 110 substantially as set forth in <400>5 or <400>6.

114 (NEW) An isolated protein or derivative, homologue, analogue, chemical equivalent or mimetic thereof wherein said protein is ELF5 which ELF5 comprises an Ets domain.

115 (NEW) An isolated protein comprising an amino acid sequence substantially as set forth in <400>2 or a derivative, homologue or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

116 (NEW) An isolated protein according to Claim 115 encoded by a nucleotide sequence substantially as set forth in <400>1 or a derivative, homologue or analogue thereof or capable of hybridizing to <400>1 under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

117 (NEW) An isolated protein according to Claim 115 substantially as set forth in <400>2.

118 (NEW) An isolated protein having an amino acid sequence substantially as set forth in <400>4 or a derivative, homologue or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>4 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

119 (NEW) An isolated protein according to Claim 118 encoded by a nucleotide sequence substantially as set forth in <400>3 or a derivative, homologue or mimetic thereof or capable of hybridizing to <400>3 under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

Appl. No. : 09/786,043  
Filed : February 27, 2001

<sup>120</sup> (NEW) An isolated protein according to Claim 118 substantially as set forth in <400>4.

<sup>121</sup> (NEW) An isolated protein comprising an amino acid sequence substantially as set forth in <400>7 or a derivative, homologue or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>7 or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

<sup>122</sup> (NEW) An isolated protein according to Claim 121 encoded by a nucleotide sequence substantially as set forth in one of <400>5 or <400>6 or a derivative, homologue or mimetic thereof or capable of hybridizing to one of <400>5 or <400>6 under low stringency conditions or a derivative, homologue, analogue, chemical equivalent or mimetic of said protein.

<sup>123</sup> (NEW) An isolated protein according to Claim 121 substantially as set forth in <400>7.

<sup>124</sup> (NEW) An isolated protein according to Claim 114 which protein is a homodimer.

<sup>125</sup> (NEW) An isolated protein according to Claim 114 which protein is a heterodimer.

<sup>126</sup> (NEW) A method of modulating expression of *ELF5* in a mammal, said method comprising contacting the *ELF5* gene with an effective amount of an agent for a time and under conditions sufficient to modulate expression of *ELF5*.

<sup>127</sup> (NEW) A method of modulating the functional activity of *ELF5* in a mammal, said method comprising administering to said mammal a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease the *ELF5* activity.

<sup>128</sup> (NEW) A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *ELF5* or sufficient to modulate the activity of *ELF5*.

<sup>129</sup> (NEW) A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of a protein according to Claim 114 or a derivative, homologue, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the functional activity of said cell.

130. (NEW) A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of a nucleic acid molecule according to Claim 101 or a derivative, homologue, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the functional activity of said cell.

131. (NEW) A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *ELF5* or sufficient to modulate the activity of *ELF5* wherein said *ELF5* expression product or *ELF5* modulates the activity of said cell.

132. (NEW) A method according to any one of Claim 128 wherein said functional activity is proliferation.

133. (NEW) A method according to Claim 132 wherein said cell is a neoplastic epithelial cell and said modulation is down-regulation.

134. (NEW) A method according to Claim 133 wherein said neoplastic epithelial cell is of breast, prostate or lung origin.

135. (NEW) A method for the treatment and/or prophylaxis of a condition characterized by the aberrant, unwanted or otherwise inappropriate cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *ELF5* wherein said modulation results in modulation of cellular functional activity.

136. (NEW) A method for the treatment and/or prophylaxis of a condition characterized by the aberrant, unwanted or otherwise inappropriate cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the activity of *ELF5* wherein said modulation results in modulation of cellular functional activity.

137. (NEW) A method for the treatment and/or prophylaxis of a condition characterized by the aberrant, unwanted or otherwise inappropriate cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of a protein according to Claim 114 or a derivative, homologue, analogue, chemical equivalent or

Appl. No. : 09/786,043  
Filed : February 27, 2001

mimetic thereof for a time and under conditions sufficient to modulate cellular functional activity.

<sup>138.</sup> (NEW) A method for the treatment and/or prophylaxis of a condition characterized by the aberrant, unwanted or otherwise inappropriate cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of a nucleic acid molecule according to Claim 101 or a derivative, homologue, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate cellular functional activity.

<sup>139.</sup> (NEW) A method of treating a mammal according to any one of Claims 135-138 wherein said condition is an epithelial cell malignancy.

<sup>140.</sup> (NEW) A method according to Claim 139 wherein said malignant epithelial cell is of breast, prostate or lung origin.

<sup>141.</sup> (NEW) A method according to Claim 139 wherein said functional activity is proliferation and said modulation is down-regulation.

<sup>142.</sup> (NEW) A pharmaceutical composition comprising *ELF5*, *ELF5* or an agent capable of modulating *ELF5* expression or *ELF5* activity or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.

<sup>143.</sup> (NEW) An isolated antibody directed to the protein according to Claim 114.

<sup>144.</sup> (NEW) An isolated antibody directed to the nucleic acid molecule according to Claim 101.

<sup>145.</sup> (NEW) The antibody according to Claim 143 or 144 wherein said antibody is a monoclonal antibody.

<sup>146.</sup> (NEW) The antibody according to Claim 143 or 144 wherein said antibody is a polyclonal antibody.

<sup>147.</sup> (NEW) A method of diagnosing or monitoring a mammalian disease condition, which disease condition is characterized by aberrant cellular functional activity, said method comprising screening for *ELF5* or *ELF5* in a biological sample isolated from said mammal.

Appl. No. : 09/786,043  
Filed : February 27, 2001

156 148. (NEW) A method for detecting an agent capable of modulating the function of ELF5 or its functional equivalent or derivative thereof said method comprising contacting a cell or extract thereof containing said ELF5 or its functional equivalent or derivative with a putative agent and detecting an altered expression phenotype associated with said ELF5 or its functional equivalent or derivative.

157 149. (NEW) A method for detecting an agent capable of modulating the function of ELF5 or its functional equivalent or derivative thereof said method comprising contacting an epithelial cell containing said ELF5 or its functional equivalent or derivative with a putative agent and detecting an altered proliferation rate.

158 150. (NEW) A method for detecting an agent capable of binding or otherwise associating with an ELF5 binding site or functional equivalent or derivative thereof said method comprising contacting a cell containing said ELF5 binding site or functional equivalent or derivative thereof with a putative agent and detecting an altered expression phenotype associated with modulation of the function of ELF5 or its functional equivalent or derivative.

Patent Application  
Serial No. 09/786,043  
Date 1/26/01